Search

Your search keyword '"Uriona S"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Uriona S" Remove constraint Author: "Uriona S"
32 results on '"Uriona S"'

Search Results

3. ESICM LIVES 2016: part three: Milan, Italy. 1–5 October 2016

4. Características de los pacientes con enfermedad neumocócica invasora que requieren ingreso en la unidad de cuidados intensivos

5. Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente

6. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

7. Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain

8. Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era

9. Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study

13. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era

15. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

17. ESICM LIVES 2016: part three : Milan, Italy. 1-5 October 2016

18. ESICM LIVES 2016: part three

19. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

20. Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine.

21. Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.

22. Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.

23. [Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine].

24. [Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units].

25. Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era.

26. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.

27. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era.

28. A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.

29. Geographic patterns and environmental factors associated with human yellow fever presence in the Americas.

30. [Influenza vaccination coverage in children with risk conditions in Catalonia].

31. [Patient characteristics and health care burden during the influenza A (H1N1) 2009 pandemic in the university Hospital Vall d'Hebron of Barcelona].

32. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.

Catalog

Books, media, physical & digital resources